VistaGen Therapeutics, Inc. (NASDAQ:VTGN) Receives Consensus Recommendation of “Reduce” from Brokerages

VistaGen Therapeutics, Inc. (NASDAQ:VTGN) has earned a consensus recommendation of “Reduce” from the five ratings firms that are presently covering the stock, MarketBeat reports. One equities research analyst has rated the stock with a sell recommendation and four have issued a hold recommendation on the company. The average 12 month price objective among brokerages that have issued a report on the stock in the last year is $0.95.

A number of research analysts have recently issued reports on the stock. Weiss Ratings reiterated a “sell (d-)” rating on shares of VistaGen Therapeutics in a research note on Wednesday, January 21st. William Blair restated a “market perform” rating on shares of VistaGen Therapeutics in a research report on Wednesday, December 17th. Wall Street Zen raised VistaGen Therapeutics from a “sell” rating to a “hold” rating in a report on Saturday, February 14th. Stifel Nicolaus downgraded VistaGen Therapeutics from a “buy” rating to a “hold” rating and set a $1.00 price objective for the company. in a research report on Wednesday, December 17th. Finally, Maxim Group reissued a “hold” rating on shares of VistaGen Therapeutics in a research note on Wednesday, December 17th.

VistaGen Therapeutics Stock Performance

VTGN opened at $0.61 on Monday. The firm has a market cap of $24.08 million, a price-to-earnings ratio of -0.32 and a beta of 0.29. The firm’s 50-day simple moving average is $0.61 and its 200-day simple moving average is $2.55. VistaGen Therapeutics has a twelve month low of $0.43 and a twelve month high of $5.14.

VistaGen Therapeutics (NASDAQ:VTGN) last announced its quarterly earnings results on Thursday, February 12th. The company reported ($0.45) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.51) by $0.06. The firm had revenue of $0.30 million for the quarter, compared to the consensus estimate of $0.14 million. As a group, sell-side analysts anticipate that VistaGen Therapeutics will post -1.77 EPS for the current fiscal year.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Cubist Systematic Strategies LLC bought a new stake in VistaGen Therapeutics during the 1st quarter worth about $25,000. Schonfeld Strategic Advisors LLC bought a new position in shares of VistaGen Therapeutics in the third quarter worth about $39,000. Millennium Management LLC acquired a new position in shares of VistaGen Therapeutics during the third quarter worth approximately $73,000. Bank of America Corp DE lifted its position in shares of VistaGen Therapeutics by 1,068.0% during the fourth quarter. Bank of America Corp DE now owns 21,141 shares of the company’s stock worth $62,000 after purchasing an additional 19,331 shares in the last quarter. Finally, GSA Capital Partners LLP bought a new stake in shares of VistaGen Therapeutics during the third quarter valued at approximately $112,000. Institutional investors and hedge funds own 78.39% of the company’s stock.

About VistaGen Therapeutics

VistaGen Therapeutics, Inc (NASDAQ:VTGN) is a clinical-stage biopharmaceutical company dedicated to the discovery and development of next-generation medicines for central nervous system disorders. Incorporated in Delaware in 1998 and headquartered in South San Francisco, California, VistaGen applies advanced human pluripotent stem cell technologies to accelerate drug candidate validation and optimization. The company’s core focus is on addressing unmet medical needs in major depressive disorder, neuropathic pain and dermatological conditions.

The company’s lead candidate, AV-101, is an oral prodrug designed to modulate glutamatergic neurotransmission via the N-methyl-D-aspartate (NMDA) receptor pathway, with clinical programs targeting major depressive disorder and neuropathic pain.